Human monoclonal antibodies that block infection with SARS-CoV-2 are being used to treat COVID-19 patients, but an alternative, antibodies produced in camelids (alpacas and llamas) might have advantages. Camelid monoclonal antibodies can be more cheaply produced in mass quantities in bacteria, and protein engineering can be quickly used to produce ...

by Gertrud U. Rey It is now a little more than a year since the emergence of SARS-CoV-2, and we already have several highly effective vaccines against this virus. Because of my previous research experience in vaccine science, I was very skeptical about the promise of a SARS-CoV-2 vaccine this ...

by Paul Bieniasz Dr. Bieniasz is Professor and Investigator of the Howard Hughes Medical Institute at Rockefeller University. As viruses go, SARS-CoV-2, is quite easy to neutralize with antibodies and, it turns out, straightforward to generate effective vaccines based on the spike protein. Perhaps, even probably, those two properties are ...

A variant of SARS-CoV-2 has been spreading within England, and it has been suggested that this virus is more transmissible. In this video Vincent explains the properties of the SARS-CoV-2 UK variant and why claims that it is more transmissible are not supported by experimental data. This video was recorded ...

by Helen Stillwell The results from a phase I clinical trial to test the safety and immunogenicity of a universal flu vaccine candidate reported encouraging results €“ strong titers of broad and functional antibodies persisted for over a year in healthy adults following vaccination.  Influenza viruses contain segmented RNA genomes. The viral ...